Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.45 |
| ▸ | GAA | P10253 | 12/20 | 0.45 |
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287284 | 0.95 | KCNN4 (0.39) | MAPTGAATP53THRBKCNN4 | |
| SCHEMBL2288165 | 0.87 | MAPT (0.47) | MAPTGAATP53THRBKCNN4 | |
| SCHEMBL2288199 | 0.86 | MAPT (0.41) | MAPTGAATP53THRBKCNN4 | |
| SCHEMBL2289661 | 0.83 | MAPT (0.40) | MAPTGAATP53THRBSMN1; SMN2 | |
| SCHEMBL2291247 | 0.83 | MAPT (0.39) | MAPTGAATP53THRBSMN1; SMN2 | |
| SCHEMBL2290088 | 0.83 | MAPT (0.39) | MAPTGAATP53THRBKCNN4 | |
| SCHEMBL2292004 | 0.83 | GAA (0.46) | MAPTGAATP53KCNN4ADORA1 | |
| SCHEMBL2289607 | 0.83 | MAPT (0.39) | MAPTGAATP53THRBPOLB | |
| SCHEMBL2287174 | 0.82 | GAA (0.44) | MAPTGAATP53KCNN4ADORA1 | |
| SCHEMBL2295279 | 0.81 | GAA (0.48) | MAPTGAATP53THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | claimed |
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAPT 1138/4885GAA 1202/4885TP53 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.